Evolus Inc. will launch a fourth neurotoxin to reduce frown lines into a competitive medical aesthetics market in Spring 2019 following US FDA approval of Jeuveau (prabotulinumtoxinA). The company believes its singular focus on the beauty business will be a differentiating factor as it goes up against Allergan PLC's blockbuster Botox (onabotulinumtoxinA) and two other well-known products.
The FDA approved Jeuveau on Feb. 1 for temporary improvement in the appearance of moderate to severe glabellar lines – also known as frown lines or forehead wrinkles – associated with corrugator and/or procerus muscle activity in adults. But while other neurotoxins are approved for use in both aesthetic and therapeutic indications, Newport Beach, Calif
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?